Skip to main content

Research Repository

Advanced Search

All Outputs (7)

The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma (2019)
Journal Article
Oguh-Olayinka, L., Agarwal, V., Ranatunge, D., Campbell, A., Laufer, S., Cawkwell, L., & Lind, M. J. (2020). The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma. Pathology and Oncology Research, 26(2), 985-995. https://doi.org/10.1007/s12253-019-00652-x

Advanced malignant pleural mesothelioma (MPM) has an extremely poor prognosis with limited chemotherapy options, therefore the identification of new therapeutic targets would aid in disease management. Arachidonic acid is metabolised by cyclooxygenas... Read More about The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma.

Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker (2014)
Journal Article
Garimella, V., Hussain, T., Agarwal, V., Radhakrishna, S., Fox, J. N., Kneeshaw, P. J., Long, E. D., Mahapatra, T. K., McManus, P. L., Lind, M. J., Drew, P. J., & Cawkwell, L. (2014). Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker. International journal of surgery, 12(8), 821-826. https://doi.org/10.1016/j.ijsu.2014.06.009

Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past. Aromatase inhibitors may be more beneficial than tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to retro... Read More about Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. https://doi.org/10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More about PTEN protein expression in malignant pleural mesothelioma.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer (2012)
Journal Article
Hodgkinson, V. C., Agarwal, V., ElFadl, D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M., & Cawkwell, L. (2012). Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 75(9), 2745-2752. https://doi.org/10.1016/j.jprot.2012.03.049

Neoadjuvant chemotherapy is used to treat oestrogen receptor-positive breast cancer however chemo-resistance is a major obstacle in this molecular subtype. The ability to predict tumour response would allow chemotherapy administration to be directed... Read More about Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? (2012)
Journal Article
Hodgkinson, V. C., ELFadl, D., Agarwal, V., Garimella, V., Russell, C., Long, E. D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M. J., & Cawkwell, L. (2012). Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 75(4), 1276-1283. https://doi.org/10.1016/j.jprot.2011.11.005

Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for estrogen receptor-positive breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only thos... Read More about Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? (2010)
Journal Article
Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), 533-542. https://doi.org/10.1016/j.ctrv.2010.11.004

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant... Read More about Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?.